Napolitano Maddalena, di Vico Francesca, Ruggiero Angelo, Fabbrocini Gabriella, Patruno Cataldo
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Campania, Italy.
Front Med (Lausanne). 2023 Apr 18;10:1165098. doi: 10.3389/fmed.2023.1165098. eCollection 2023.
Recent evidence suggests that interleukin (IL)-13 is a crucial cytokine involved in the pathogenesis of atopic dermatitis (AD). It is a central driver of type-2 T-helper inflammation and is overexpressed in lesional skin of AD patients. Upon release in peripheral skin, IL-13 activates its receptors, recruits inflammatory cells, and modifies the skin microbiome. IL-13 also reduces the expression of epidermal barrier proteins and activates sensory nerve mediating the itch transmission signal. Novel therapeutics that target IL-13 seem to be efficacious and safe for the treatment of patients with moderate-to-severe AD. The aim of our manuscript is to review the role that IL-13 plays in AD immunopathogenesis.
最近的证据表明，白细胞介素（IL）-13是参与特应性皮炎（AD）发病机制的关键细胞因子。它是2型辅助性T细胞炎症的核心驱动因素，在AD患者的皮损中过度表达。在周围皮肤中释放后，IL-13激活其受体，募集炎症细胞，并改变皮肤微生物群。IL-13还会降低表皮屏障蛋白的表达，并激活介导瘙痒传递信号的感觉神经。针对IL-13的新型疗法似乎对中重度AD患者的治疗有效且安全。我们这篇文章的目的是综述IL-13在AD免疫发病机制中所起的作用。
